Idexx Laboratories (IDXX) Accumulated Expenses (2009 - 2026)

Idexx Laboratories has reported Accumulated Expenses for 18 years, with the latest figure at $453.2 million in Q2 2026.

• On a quarterly basis, Accumulated Expenses rose 8.68% year-over-year to $453.2 million in Q2 2026; TTM through Jun 2026 was $453.2 million, a 8.68% increase from a year earlier, with the FY2025 full-year figure at $530.1 million, up 5.58% from the prior year.
• Accumulated Expenses was $453.2 million for Q2 2026 at Idexx Laboratories, roughly flat from $453.6 million in the prior quarter.
• The five-year high for Accumulated Expenses was $541.1 million in Q2 2024, with the low at $387.5 million in Q2 2022.
• Average Accumulated Expenses over 5 years is $455.7 million, with a median of $453.4 million recorded in 2026.
• The sharpest annual moves came in 2024 and 2025: Accumulated Expenses jumped 35.48% in 2024, then fell 22.94% in 2025.
• Over 5 years, Accumulated Expenses stood at $433.7 million in 2022, then advanced by 10.39% to $478.7 million in 2023, then climbed by 4.89% to $502.1 million in 2024, then advanced by 5.58% to $530.1 million in 2025, then dropped by 14.52% to $453.2 million in 2026.
• The last three Accumulated Expenses figures came in at $453.2 million (Q2 2026), $453.6 million (Q1 2026), and $530.1 million (Q4 2025), per Business Quant data.